212 results
Page 3 of 11
6-K
w37q5
11 Sep 23
Current report (foreign)
6:50am
6-K
us7be0nn si
1 Aug 23
Current report (foreign)
6:10am
6-K
EX-99.1
kbksq slwcqv018m3qn
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
itw8uuz7jgut
12 Jul 23
Current report (foreign)
6:07am
6-K
EX-99.1
857sw4uqniuy9w
6 Jul 23
Current report (foreign)
6:18am
6-K
bjc2gz3tn2go
28 Jun 23
Current report (foreign)
6:02am
6-K
EX-99.1
c2aqts5m yzv
23 Jun 23
Current report (foreign)
6:13am
6-K
k8jyo oo5h0
30 May 23
Current report (foreign)
6:20am
6-K
EX-99.1
54p3g2 6htpxihbzxwi
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
nt22b msnyhkcvu
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
knppwau4hphz
30 May 23
Current report (foreign)
6:11am
6-K
ktaz4e
17 May 23
Current report (foreign)
6:02am
6-K
36t5qd45jgueiq qj3
11 May 23
Current report (foreign)
6:10am
6-K
1sni58
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
3c4dzk81oqr
11 May 23
Current report (foreign)
6:07am
6-K
rfvvggyb5tx3zbxzy149
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
4ki0cgbw2bqxcfkm
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
jrgzpe 9fyccvhn
8 Dec 22
Current report (foreign)
6:46am
6-K
EX-99.1
w8i1fd9a29h8vf
30 Nov 22
Current report (foreign)
6:28am